S2O2 finalizes acquisition of Texas-based sanitation technology innovator

Neutra Corp. (OTCBB: NTRR), a growing provider of all-natural wellness solutions, announced today that its joint venture partner Surface to Air Solutions (S2O2) is finalizing the acquisition of a sanitation technology innovator dedicated to greatly reducing the risk of staph infection in sports.

S2O2 is acquiring a Texas-based firm that has a potentially lucrative anti-microbial coating capable of adhering to sporting equipment and facilities, preventing viral and bacterial contamination. In addition to preventing the spread of common diseases and illnesses from the flu to H1N1, the technology could prove especially useful in combatting the antibiotic-resistant strain of staph known as methicillin-resistant Staphylococcus aureus (MRSA).

"This is a high-upside acquisition by our partner that we feel will make a real difference in the fight to protect athletes large and small," said NTRR CEO Sydney Jim. "We look forward to working with them to help develop and market this innovative new coating as well as related products to a marketplace hungry for all-natural solutions."

Source:

Neutra Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists unveil a 3D photoacoustic scanner that speeds up vascular imaging for real-time clinical use